Mar 28 |
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
|
Mar 28 |
Gilead bets on Xilio cancer drug as biotech restructures
|
Feb 28 |
Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference
|
Jan 31 |
Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference
|
Jan 8 |
Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies
|
Dec 7 |
Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data
|